Loading...
Please wait, while we are loading the content...
Similar Documents
Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
| Content Provider | Scilit |
|---|---|
| Author | Zhang, Di Huang, Jiaqi Sun, Yulan Guo, Qisen |
| Copyright Year | 2019 |
| Description | Abstract: Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor receptor-2 inhibitor, has shown notable therapeutic effect in a wide variety of tumors. We report a woman with advanced ovarian cancer who received apatinib at 250 mg/day after failure of multiple-line treatment regimens, followed by discussion through review of literature. The patient has quite a long progression-free survival time of 24 months, with a satisfactory quality of life. Apatinib monotherapy may provide an additional option for advanced ovarian cancer,but it still needs further observation and exploration. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529614/pdf https://www.dovepress.com/getfile.php?fileID=49878 |
| Ending Page | 3644 |
| Page Count | 10 |
| Starting Page | 3635 |
| ISSN | 11786930 |
| DOI | 10.2147/ott.s198946 |
| Journal | OncoTargets and therapy |
| Volume Number | 12 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2019-05-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Oncotargets and Therapy Obstetrics and Gynecology Anti-angiogenic Therapy Apatinib Monotherapy Ovarian Cancer Vascular Endothelial Growth Factor Receptor |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |